Dyadic International, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 08, 2023 at 04:06 pm EST
Share
Dyadic International, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported revenue was USD 0.39706 million compared to USD 0.879597 million a year ago. Net loss was USD 1.61 million compared to USD 1.81 million a year ago. Basic loss per share from continuing operations was USD 0.06 compared to USD 0.06 a year ago.
For the nine months, revenue was USD 2.21 million compared to USD 2.19 million a year ago. Net loss was USD 4.72 million compared to USD 7.59 million a year ago. Basic loss per share from continuing operations was USD 0.16 compared to USD 0.27 a year ago.
Dyadic International, Inc. is a biotechnology company focused on the large-scale manufacture of proteins for use in human and animal vaccines and therapeutics and for use in non-pharmaceutical applications including food, nutrition, and wellness. The Company's gene expression and protein production platforms are based on the highly productive and scalable fungus Thermothelomyces heterothallica (formerly Myceliophthora thermophila). Its lead technology, C1-cell protein production platform, is based on an industrially proven microorganism (named C1), which is used to speed development and improve performance of biologic vaccines and drugs at flexible commercial scales for the human and animal health markets. The Company has also developed the Dapibus filamentous fungal based microbial protein production platform to enable the rapid development and large-scale manufacture of low-cost proteins, metabolites, and other biologic products for use in non-pharmaceutical applications.
DYADIC INTERNATIONAL, INC. 
